Date: 2012-06-18
Type of information:
Compound: candidate vaccines
Company: Bavarian Nordic (Denmark) National Institute of Allergy and Infectious Diseases (NIAID) (USA)
Therapeutic area: Infectious diseases - Cancer- Oncology
Type agreement: R&D
development
Action mechanism: These candidate vaccines will be based on Bavarian Nordic's recombinant MVA-BN® technology platform.
Disease: smallpox, infectious diseases, cancer
Details: Bavarian Nordic has announced that it has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, valued up to $ 17.9 million over five years. The new contract will support the advanced development of candidate vaccine components and technologies that accelerate the immune response for use in post-event settings following the intentional release of pathogens that are considered a threat to public health.
Under the contract, Bavarian Nordic will evaluate several novel technologies to accelerate and/or enhance the immune response to a combined smallpox and Marburg virus vaccine based on MVA-BN®. Although both diseases are considered priority pathogens by the US government, if successful, the new technologies would have benefits for all MVA-BN®-based vaccines for infectious disease and cancer.
Under the 2 year base period of the contract, valued at $4.4 million, Bavarian Nordic would evaluate several candidate vaccines in preclinical studies. This may be followed by GMP production and a Phase I clinical trial for the lead candidate that will be performed under several contract options that may be exercised until the end of the contract in 2017.
Financial terms: The contract is valued up to $ 17.9 million over five years.
Latest news:
